StocksTelegraph
S&P 500—NASDAQ—DOW—RUSSELL—
NASDAQ · MRKR·Healthcare

Marker Therapeutics, Inc. Stock Analysis & AI Score

Marker Therapeutics, Inc. (MRKR) has an ST Score of 38.5 (C), driven by its Financial Strength (B) and held back by its Profitability (D+). Analysts rate it Buy.

Market Open
$1.16
Prev Close
—
Market Cap
—
Day Range
—
52W Range
—
P/E
—
EPS (TTM)
—
Volume
—
Avg —
Beta
—
39
ST Score
38.5/100C

Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.

As of

AI Daily Briefing

Analysis by AI

MRKR Stock Price History

—

MRKR Technical Indicators

FMP

Earnings Surprises

Analyst Forecast

Revenue Mix

Company Information

Employees—
CEO—
SectorHealthcare
IndustryBiotechnology
IPO Date—
Website—
Country—
ExchangeNASDAQ

SEC Filings

Annual Report (10-K)

Filing DateAcceptedLink
Loading…

Quarterly Report (10-Q)

Filing DateAcceptedLink
Loading…

Analyst Price Target

ESG Score

MRKR Latest Stock News

ST Score

MRKR
38.5out of 100
Grade C

Marker Therapeutics, Inc. (MRKR) has an ST Score of 38.5 (C), driven by its Financial Strength (B) and held back by its Profitability (D+). Analysts rate it Buy.

Strongest
Financial StrengthB
Weakest
ProfitabilityD+
All factor grades
  • Financial StrengthB
  • ValuationC+
  • MomentumC
  • GrowthC-
  • ProfitabilityD+
  • Piotroski2/9
Score methodology

Press Releases

Company Contact Details

MRKR stock: frequently asked questions

What is MRKR's ST Score?

Marker Therapeutics, Inc. (MRKR) has an ST Score of 38.5 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Is MRKR a buy, hold, or sell?

Analysts rate MRKR a Buy. Our ST Score grades it C (38.5/100). The ST Score is a data-driven signal, not a recommendation.

What are MRKR's factor grades?

Valuation C+, Profitability D+, Financial Strength B, Momentum C, Growth C-.

What is MRKR's valuation grade?

Marker Therapeutics, Inc. (MRKR) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

What is MRKR's growth grade?

Marker Therapeutics, Inc. (MRKR) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

What is MRKR's profitability grade?

Marker Therapeutics, Inc. (MRKR) earns a profitability grade of D+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

What is MRKR's financial strength grade?

Marker Therapeutics, Inc. (MRKR) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

What is MRKR's Piotroski score?

Marker Therapeutics, Inc. (MRKR) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.